1. Home
  2. SDOT vs NEUP Comparison

SDOT vs NEUP Comparison

Compare SDOT & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SDOT

Sadot Group Inc.

HOLD

Current Price

$14.51

Market Cap

23.1M

ML Signal

HOLD

Logo Neuphoria Therapeutics Inc.

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$3.76

Market Cap

20.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDOT
NEUP
Founded
2014
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
23.1M
20.6M
IPO Year
2019
2002

Fundamental Metrics

Financial Performance
Metric
SDOT
NEUP
Price
$14.51
$3.76
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
2.1M
51.1K
Earning Date
04-29-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
490.91
N/A
EPS
N/A
N/A
Revenue
$7,929,137.00
$15,649,448.00
Revenue This Year
$12.76
N/A
Revenue Next Year
$5.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
60.08
N/A
52 Week Low
$0.14
$3.19
52 Week High
$106.00
$21.31

Technical Indicators

Market Signals
Indicator
SDOT
NEUP
Relative Strength Index (RSI) 51.42 45.75
Support Level $1.81 $3.75
Resistance Level $35.50 $4.15
Average True Range (ATR) 3.26 0.15
MACD 0.92 -0.01
Stochastic Oscillator 33.12 12.70

Price Performance

Historical Comparison
SDOT
NEUP

About SDOT Sadot Group Inc.

Sadot Group Inc consisted of one distinct operating unit engaged in the Agri-Foods industry. Its operating unit was intended to be a Agri-Foods company engaged in farming, commodity trading and shipping of food and feed (e.g., soybean meal, wheat and corn) via dry bulk cargo ships across the globe.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: